ClearPoint Neuro Updates Director Compensation Plan

The latest announcement is out from ClearPoint Neuro ( (CLPT) ).

ClearPoint Neuro, Inc. has revised its Non-Employee Director Compensation Plan to attract and retain qualified board members by offering appropriate compensation. The updated plan, last revised on May 22, 2023, reflects the company’s commitment to strong corporate governance practices.

The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

Spark’s Take on CLPT Stock

According to Spark, TipRanks’ AI Analyst, CLPT is a Neutral.

ClearPoint Neuro’s overall stock score reflects its robust revenue growth and strategic initiatives, which are offset by ongoing profitability challenges and mixed technical indicators. The company’s solid financial backing and growth potential in the medical devices industry are key strengths, but the valuation remains a concern.

To see Spark’s full report on CLPT stock, click here.

More about ClearPoint Neuro

ClearPoint Neuro, Inc. operates in the medical technology industry, focusing on providing innovative solutions for neurosurgery. The company specializes in products and services that enhance precision and accuracy in neurological procedures.

Average Trading Volume: 281,240

Technical Sentiment Signal: Buy

Current Market Cap: $372.5M

Find detailed analytics on CLPT stock on TipRanks’ Stock Analysis page.